ArticleJournal of controlled release : official journal of the Controlled Release Society2016
Intraperitoneal chemotherapy of ovarian cancer by hydrogel depot of paclitaxel nanocrystals.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Peritoneal chemotherapy delivery systems for ovarian cancer treatment: systematic review of animal models.Frontiers in oncology · 2024Pooled it
- Hydrogel-Based intraperitoneal drug delivery platforms for peritoneal metastasis: strategies, advances, and prospects.Drug delivery · 2026Review
- Physiological Considerations and Delivery Strategies for Targeting Tumors Through Intraperitoneal Delivery.Pharmaceutical research · 2025Review
- Advances in hybrid hydrogel design for biomedical applications: innovations in drug delivery and tissue engineering for gynecological cancers.Cell biology and toxicology · 2025Review
- Innovative landscapes in intraperitoneal therapy of ovarian cancer.Drug delivery and translational research · 2025Review
- Advancements in Hydrogel-Based Therapies for Ovarian Cancer: A Review.Cell biochemistry and biophysics · 2025Review
- Evaluation of Different Commercial Sealing Hemostatic Patches for Their Selection as Reservoirs for Localized Intraperitoneal Chemotherapy.ACS pharmacology & translational science · 2025Article
- A Review of the Release Profiles and Efficacies of Chemotherapy Drug-Loaded Electrospun Membranes.Polymers · 2023Review
- Review
- Drug Nanocrystals: Focus on Brain Delivery from Therapeutic to Diagnostic Applications.Pharmaceutics · 2022Review
- Review
- SuperiorJournal of biomedical research · 2021Article
- Tuning the Physicochemical Characteristics of Particle-Based Carriers for Intraperitoneal Local Chemotherapy.Pharmaceutical research · 2020Review
- Sustained Delivery of Carfilzomib by Tannic Acid-Based Nanocapsules Helps Develop Antitumor Immunity.Nano letters · 2019Article
- Improved anti-tumor efficacy of paclitaxel in combination with MicroRNA-125b-based tumor-associated macrophage repolarization in epithelial ovarian cancer.Cancer letters · 2019Article
- Hollow gold nanoshells-incorporated injectable genetically engineered hydrogel for sustained chemo-photothermal therapy of tumor.Journal of nanobiotechnology · 2019Article
- Enhanced anti-tumor efficacy and safety with metronomic intraperitoneal chemotherapy for metastatic ovarian cancer using biodegradable nanotextile implants.Journal of controlled release : official journal of the Controlled Release Society · 2019Article
- Aerosolization of Nanotherapeutics as a Newly Emerging Treatment Regimen for Peritoneal Carcinomatosis.Cancers · 2019Review
- Thermosensitive Injectable Hydrogel for Simultaneous Intraperitoneal Delivery of Doxorubicin and Prevention of Peritoneal Adhesion.International journal of molecular sciences · 2018Article
- Slow-Release Formulation of Cowpea Mosaic Virus for In Situ Vaccine Delivery to Treat Ovarian Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Intraperitoneal (IP) chemotherapy is a promising post-surgical therapy of ovarian cancer, but the full potential is yet to be realized. To facilitate IP chemotherapy of ovarian cancer, we developed an in-situ crosslinkable hydrogel depot containing paclitaxel (PTX) nanocrystals (PNC). PNC suppressed SKOV3 cell proliferation more efficiently than microparticulate PTX precipitates (PPT), and the gel containing PNC (PNC-gel) showed a lower maximum tolerated dose than PPT-containing gel (PPT-gel) in mice, indicating greater dissolution and cellular uptake of PNC than PPT. A single IP administration of PNC-gel extended the survival of tumor-bearing mice significantly better than Taxol, but PPT-gel did not. These results support the advantage of PNC over PPT and demonstrate the promise of a gel depot as an IP drug delivery system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.